Research programme: idiopathic pulmonary fibrosis therapeutic - MAbImprove/SanofiAlternative Names: Antibody therapeutic inhaled spray - MAbImprove/Sanofi
Latest Information Update: 02 Sep 2014
At a glance
- Originator MAbImprove; Sanofi
- Class Antibodies
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Idiopathic pulmonary fibrosis
Most Recent Events
- 24 Jan 2014 Early research in Idiopathic pulmonary fibrosis in France (Inhalation)